Champions Oncology (CSBR) Posts Narrower Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue Growth
September 9, 2016 8:15 AM EDTHACKENSACK, N.J., Sept. 9, 2016 /PRNewswire/ --Â Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2016.
First Quarter and Recent Business Highlights:
First quarter revenue of $3.7 million; significantly above revenue guidance range of $3.25 - $3.5 million Reaffirms full year revenue guidance for FY2017 of $16 - $18 million Delivered third consecutive quarter of record TOS bookings Signed significant AML study with major... More